Indication
Monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Medicine details
- Medicine name:
- belantamab mafodotin (Blenrep)
- SMC ID:
- SMC2597
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 15 January 2024
- SMC meeting date:
- 05 December 2023
- Patient group submission deadline:
- 02 October 2023